Matinas BioPharma Holdings, Inc.
MTNBNYSE
$0.34
↓ -3.6%Jul 17 close · end-of-day
Price
1Y↓ -65.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.2M
Enterprise Value
-$196,832.77
P/E
—
P/S
—
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$10.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-351.1%
ROIC
-879.9%
Debt / Equity
—
Net Cash
$2.4M
Return 1Y
-64.2%
Company profile
Matinas BioPharma Holdings, Inc. focuses on the discovery and development of various product candidates. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.
- CEO
- Jerome D. Jabbour
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- New Jersey
- Website
- matinasbiopharma.com
Earnings
MTNB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.30↓ -9.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $158,333.00 | $33,000.00 | $3.2M | $1.1M | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$24.2M | -$24.7M | -$24.6M | -$23.8M | -$24.6M | -$7.0M |
| Net income | -$22.4M | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| Diluted EPS | — | — | -$0.10 | -$5.28 | -$4.98 | -$2.00 |
| Operating cash flow | -$17.4M | -$15.2M | -$19.2M | -$15.3M | -$15.9M | -$7.0M |
| Free cash flow | -$17.4M | -$15.5M | -$20.0M | -$15.5M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -15288.4% | -74954.5% | -771.3% | -2168.4% | — | — |
| Net margin | -14177.0% | -70554.5% | -658.6% | -2093.2% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.8M | -$4.4M | -$8.5M | -$1.9M | -$1.8M | -$1.6M | -$1.6M | -$1.9M |
| Net income | -$5.7M | -$4.3M | -$8.4M | -$1.7M | -$5.2M | -$1.5M | -$1.9M | -$1.9M |
| Diluted EPS | -$1.15 | -$0.85 | -$1.64 | -$0.33 | -$1.03 | -$0.40 | -$0.24 | -$0.30 |
| Operating cash flow | -$3.1M | -$3.5M | -$3.5M | -$2.0M | -$2.0M | -$1.5M | -$1.5M | -$1.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 13, 2026
- 7d agoGH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharmafinance.yahoo.com
- 7d agoMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticalsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.